Can I read Association between EGFR Polymorphism and Recurrence-free Survival in Prostate Cancer on EtoBox?

Association between EGFR Polymorphism and Recurrence-free Survival in Prostate Cancer by C.A. Perez; H. Chen; J. Jaboin; M. Wills; R. Courtney; J.N. Roberts; Q. Cai; B. Lu is a Medicine article available to read on EtoBox.

What is Association between EGFR Polymorphism and Recurrence-free Survival in Prostate Cancer about?

Median PSA was 12 ng/ml (0.9 -20), #10 and .10 ng/ml in 33.8% and 66.2%, respectively. Median RT dose was prescribed on the ICRU point and delivered through a 3D conformal therapy. Pelvic irradiation (median dose 46 Gy [45 -46]) was performed in 325 pts (48.6%). HT (median time 5.6 months [3 -29]) was used in 394 pts (59%). The median follow-up of 50.8 months (3.6 -126.0). Using univariate analysis, use of HT (p = 0.01), RT dose $78 Gy (p = 0.024), number of IRFs\2 (p = 0.032), TG4 (p = 0.029), and GS #6 (p = 0.059) were significantly associated with a better BC. Upon multivariate analysis, HT (p = 0.021, hazard ratio [HR]: 1.57), T stage (p = 0.041, HR: 1.49), GS (p = 0.005, HR: 1.75), and RT dose (p = 0.021, HR: 1.70) were considered as independent BCPFs. PI was constructed as follows: +5 if no HT, +4 if T stage = T2b, +6 if GS = 7, and +5 if RT dose \78 Gy. BC 5-year survival rate for PI1 (PI $0, #7), PI2 (PI .7, #13), and PI3 (PI .13, #20) was 89.0%, 78.0%, and 68.8%, respectively (p = 0.00073). Conclusions: The D'Amico IRPC group appears quite homogeneous. In this sub-group, the use of a short course of HT combined with high dose RT improves significantly the BC. Applying the

Who reads Association between EGFR Polymorphism and Recurrence-free Survival in Prostate Cancer?

Author

C.A. Perez; H. Chen; J. Jaboin; M. Wills; R. Courtney; J.N. Roberts; Q. Cai; B. Lu

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2008

Language

EN

Field

Medicine (Health Sciences)